VCELVericel Corporation

$2B

Q1 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$36M+4.4% YoY

Gross Profit

$23M65.0% margin

Operating Income

-$7M-20.2% margin

Net Income

-$7M-19.7% margin

EPS (Diluted)

$-0.15

QoQ Revenue Growth

-24.2%

Cash Flow

Operating Cash Flow

$3M

Free Cash Flow

$387,000

Stock-Based Comp.

$10M

Balance Sheet

Total Assets

$240M

Total Liabilities

$68M

Stockholders' Equity

$172M

Cash & Equivalents

$56M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$36M	$35M	+4.4%
Gross Profit	$23M	$23M	+2.0%
Operating Income	-$7M	-$3M	-120.1%
Net Income	-$7M	-$3M	-115.6%

Revenue Segments

MACI Implants And Kits Member

$26M100%

VCEL Q1 2022 Earnings — Vericel Corporation Revenue & Financial Results | Market Cap Arena